See more : Hunan Hansen Pharmaceutical Co., Ltd. (002412.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Relay Therapeutics, Inc. (RLAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relay Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Text S.A. (LCHTF) Income Statement Analysis – Financial Results
- Thai Wire Products Public Company Limited (TWP.BK) Income Statement Analysis – Financial Results
- Guangbo Group Stock Co., Ltd. (002103.SZ) Income Statement Analysis – Financial Results
- Reklaim Ltd. (MYID.V) Income Statement Analysis – Financial Results
- Lee Kee Holdings Limited (0637.HK) Income Statement Analysis – Financial Results
Relay Therapeutics, Inc. (RLAY)
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 25.55M | 1.38M | 3.03M | 82.65M | 0.00 | 0.00 |
| Cost of Revenue | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| Gross Profit | 20.28M | -2.75M | -896.00K | 79.11M | -2.85M | -2.15M |
| Gross Profit Ratio | 79.37% | -199.06% | -29.58% | 95.71% | 0.00% | 0.00% |
| Research & Development | 330.02M | 246.36M | 172.65M | 99.86M | 70.31M | 41.03M |
| General & Administrative | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Other Expenses | 0.00 | -20.00K | -4.00K | -16.00K | -58.00K | -9.00K |
| Operating Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Cost & Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Interest Income | 31.05M | 8.79M | 830.00K | 3.40M | 8.80M | 1.11M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| EBITDA | -374.15M | -306.82M | -222.18M | -52.25M | -81.20M | -47.74M |
| EBITDA Ratio | -1,464.62% | -23,361.98% | -2,948.70% | -63.21% | 0.00% | 0.00% |
| Operating Income | -373.00M | -299.28M | -364.70M | -55.80M | -84.05M | -49.89M |
| Operating Income Ratio | -1,460.11% | -21,670.89% | -12,040.21% | -67.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.03M | 8.77M | 826.00K | 3.38M | 8.74M | 1.10M |
| Income Before Tax | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.79M |
| Income Before Tax Ratio | -1,338.66% | -21,036.13% | -12,012.94% | -63.41% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.25M | 132.94M | -3.40M | -8.80M | 1.10M |
| Net Income | -341.97M | -254.26M | -496.81M | -49.01M | -66.50M | -48.79M |
| Net Income Ratio | -1,338.66% | -18,411.22% | -16,401.72% | -59.30% | 0.00% | 0.00% |
| EPS | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| Weighted Avg Shares Out | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
| Weighted Avg Shares Out (Dil) | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Relay Stock Soars on Upbeat Data From Breast Cancer Study
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Source: https://incomestatements.info
Category: Stock Reports